New Delhi: The Indian Pharmacopoeia Commission (IPC) has been announced as a member of the Pharmacopoeial Discussion Group (PDG) during a Stakeholder’s meeting in Hyderabad on October 5, 2023.
IPC officially became a member of the PDG during the PDG’s Annual Meeting held on October 3-4, 2023 in Hyderabad. The PDG’s Annual Meeting was attended by various renowned professionals and organizations in the field, including the World Health Organization (WHO) in their observer capacity.
Pharmacopoeial Discussion Group (PDG)
The PDG aims to bring together the European Pharmacopoeia (Ph. Eur.), the Japanese Pharmacopoeia (JP), the United States Pharmacopeia (USP), and Indian Pharmacopoeia (IP) in order to harmonize global pharmacopoeial standards.
The objective is to alleviate the burden on manufacturers by streamlining analytical procedures and acceptance criteria. This will ensure compliance with varying pharmacopoeial requirements across different regions.
IPC’s Role
The International Pharmacopoeia Commission (IPC) was the sole pharmacopoeia body selected for the pilot phase initiated in September 2022. Following a comprehensive evaluation of each application, the Pharmacopoeial Discussion Group (PDG) unanimously agreed to commence the pilot phase with the IPC. This decision was based on the fact that the IPC was the only applicant that fulfilled all the entry criteria requirements for the pilot.
After completing the pilot phase for one year, the decision to include IPC as a permanent member of PDG was made, considering IPC’s involvement, contribution, and future potential. On 18th September, 2023, PDG sent an official letter confirming IPC’s membership in the group.
This demonstrates IPC’s unwavering commitment and proven ability to establish top-tier quality standards for drugs and pharmaceuticals.
- Inclusion of IP in PDG will significantly increase the visibility of the Indian Pharmacopoia on international platform. It will establish IP as progressive pharmacopoeia which designs drug quality standards at par with global standards. Application of these standards will lead to production of world class pharmaceutical products for domestic and export markets.
- IPC’s inclusion in PDG will help in effort towards its recognition by other countries.
- Harmonization of Standards: It will help IPC to collaborate and harmonize pharmacopoeial standards with other major regulatory/standard setting authorities which in turn will help in ensuring the quality and safety of pharmaceuticals at a global level.
- International Recognition: Membership in the PDG would enhance the international recognition of the standards set by the IPC. This also has potential to improve the acceptance of Indian pharmaceutical products in global markets, as they adhere to internationally recognized quality standards.
- Improved Regulatory Compliance: IPC will benefit from the exchange of information and best practices with other PDG members. This collaboration will help India in aligning its regulatory processes and practices with global standards, making it easier for Indian pharmaceutical companies to comply with international regulations.
- Access to Global Markets: Membership in the PDG will facilitate enhanced export of Indian pharmaceutical products to other member countries. Aligning with international standards will reduce trade barriers and make it easier for Indian pharmaceutical companies to access global markets.
- Global Health Impact: The harmonization of pharmacopoeial standards among PDG members will contribute to the global effort to ensure the safety and efficacy of marketed pharmaceutical products. This will have a direct impact on public health worldwide, as it helps to prevent the circulation of substandard or counterfeit drugs.
IPC’s membership in the PDG represents a noteworthy progression towards the advancement of pharmaceutical standards, enhancement of regulatory compliance, facilitation of international recognition, and ultimately the improvement of global public health by ensuring the quality and safety of drugs.
